Features | Discovery cohort (n = 1540) | Validation Cohort (n = 630) |
---|---|---|
Age, median (range), year | 53.0 (10–86) | 53.0 (12–92) |
Gender, male/female | 1305 (84.7%)/235 (15.3%) | 530 (84.1%)/100 (15.9%) |
α-Fetoprotein (>200/≤200 ng/dL) | 593 (38.5%)/947 (61.5%) | 259 (41.1%)/371 (58.9%) |
Liver cirrhosis, yes/no/unknown | 1268 (82.3%)/251 (16.3%)/21 (1.4%) | 512 (81.3%)/102 (16.2%)/16 (2.5%) |
Hepatitis B history, yes/no/unknown | 1255 (81.5%)/254 (16.5%)/31 (2.0%) | 527 (83.7%)/94 (14.9%)/9 (1.4%) |
Tumor size, mean ± SD, cm | 5.3 ± 3.5 | 5.5 ± 3.7 |
Tumor number, multiple/solitary | 199 (12.9%)/1341 (87.1%) | 78 (12.4%)/552 (87.6%) |
Types of resection, anatomic/non-anatomic | 1222 (79.4%)/318 (20.6%) | 475 (75.4%)/155 (24.6%) |
Encapsulation, complete/none/unknown | 733 (47.6%)/803 (52.1%)/4 (0.3%) | 294 (46.7%)/335 (53.2%)/1 (0.2%) |
Tumor differentiation, I–II/III–IV/unknown | 1098 (71.3%)/421 (27.3%)/21 (1.4%) | 441 (70.0%)/171 (27.1%)/18 (2.9%) |
Microvascular invasion, yes/no | 389 (25.3%)/1151 (74.7%) | 205 (32.5%)/425 (67.5%) |
BCLC stage, 0/A/B | 194 (12.6%)/1192 (77.4%)/154 (10.0%) | 87 (13.8%)/484 (76.8%)/59 (9.4%) |